• Publications
  • Influence
Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.
Reported are the results of a study to determine the efficacy and safety of liposomal amphotericin B (AmBisome) for treating visceral leishmaniasis (kala-azar) in several developing countries whereExpand
  • 150
  • 10
  • PDF
Post kala-azar dermal leishmaniasis: a neglected aspect of kala-azar control programmes.
Post kala-azar dermal leishmaniasis (PKDL) was studied in relation to the kala-azar epidemic in Bihar, India. Between 1970 and 1989, 530 individuals, 302 males and 228 females, were admitted to theExpand
  • 111
  • 8
Socio-economics of visceral leishmaniasis in Bihar (India).
  • C. Thakur
  • Medicine
  • Transactions of the Royal Society of Tropical…
  • 1 March 2000
  • 107
  • 5
A single high dose treatment of kala-azar with Ambisome (amphotericin B lipid complex): a pilot study.
  • C. Thakur
  • Medicine
  • International journal of antimicrobial agents
  • 2001
Thirty four patients with parasitologically confirmed visceral leishmaniasis were divided randomly into two groups of 17. Group A received Ambisome (amphotericin B lipid complex) at a dose of 15mg/kgExpand
  • 55
  • 5
Diagnosis of symptomatic visceral leishmaniasis by use of the polymerase chain reaction on patient blood.
To diagnose symptomatic visceral leishmaniasis (kala-azar) using peripheral blood rather than tissue aspirates, a polymerase chain reaction (PCR) technique was developed for which the detection limitExpand
  • 84
  • 4
Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases.
Out of 938 parasitologically confirmed patients with visceral leishmaniasis treated with amphotericin B (1 mg/kg bodyweight daily infused in 2 h for 20 days), 935 were cured clinically, 933Expand
  • 134
  • 4
Epidemiological, clinical & pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India.
BACKGROUND & OBJECTIVES Sodium antimony gluconate (SAG) is reported to be losing its efficacy in Bihar as a first line drug for treatment of visceral leishmaniasis (VL). Concerned with the increasingExpand
  • 70
  • 4
  • PDF
Skewing of cytokine profiles towards T helper cell type 2 response in visceral leishmaniasis patients unresponsive to sodium antimony gluconate.
Thirty-two parasitologically confirmed visceral leishmanisis (VL) patients and 23 healthy, age- and gender-matched controls were recruited between April 2001 and March 2002 and studied forExpand
  • 38
  • 4
Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India.
OBJECTIVES To assess the efficacy and tolerability of aminosidine compared with sodium stibogluconate for treating visceral leishmaniasis. DESIGN Randomised, unblinded, controlled trial with 180Expand
  • 162
  • 3
Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study.
The efficacy and safety of 3 regimens of liposomal amphotericin B (AmBisome) in the treatment of Indian visceral leishmaniasis were compared in a prospective open randomized trial. ThirtyExpand
  • 93
  • 3